(VIANEWS) – Shares of ImmunoGen (NASDAQ: IMGN) rose by a staggering 34.26% in 21 sessions from $4.7 at 2022-09-22, to $6.31 at 21:42 EST on Wednesday, after three consecutive sessions in a row of losses. NASDAQ is jumping 3.43% to $10,675.80, after two sequential sessions in a row of gains.

ImmunoGen’s last close was $6.09, 21.62% below its 52-week high of $7.77.

About ImmunoGen

ImmunoGen, Inc., is a biotech company in clinical stage. It develops ADC therapies for cancer. Mirvetuximab Soravtansine is an ADC which targets folate receptor alpha (FRa) and is currently in Phase III clinical trials. Pivekimab Sunirine is a CD123-targeting ADC and is currently in Phase II clinical trials to treat acute myeloid and blastic plasmacytoid cell neplasma. Preclinical programs for the company include IMGC936, an ADC co-developed with MacroGenics, Inc., and IMGN151, a anti-FRa product candidate. Collaborations include Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CymX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. ImmunoGen, Inc., was established in 1980 and has its headquarters in Waltham, Massachusetts.

Earnings Per Share

As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -100.96%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 40% and a negative 38.9%, respectively.

Sales Growth

ImmunoGen’s sales growth is negative 4.5% for the current quarter and 22.6% for the next.

More news about ImmunoGen (IMGN).